Eisai Company, Limited

Hiroshi Akamatsu

Shigeto Negi

Seiichi Kobayashi

Naoyuki Shimomura

Osamu Asano

Kenji Hayashi

Manabu Murakami

Nobuhisa Watanabe

Tsutomu Kawata

Hitoshi Harada

Takashi Inoue

Toshihiko Naito

Toshikazu Shimizu

Nobuyuki Yasuda

Junsaku Nagaoka

Seiji Yoshikawa

Tatsuo Horizoe

Isao Tanaka

Hiroe Minami

Naoki Ozeki

Kaya Ohashi

Toyokazu Haga

The present invention provides a preventive or therapeutic agent for diabetes mellitus and diabetic complications, which is a new type based on an adenosine A2 receptor antagonist action. That is, it provides a novel condensed imidazole compound which has an adenosine A2 receptor antagonist action, is effective for preventing or treating diabetes mellitus and diabetic complications, and is represented by the formula (I);(wherein Rrepresents e.g. an amino group which may be substituted with an alkyl group; Rrepresents e.g. hydrogen atom, an alkyl group, a cycloalkyl group or an alkyl group, alkenyl group or alkynyl group which may be substituted with hydrox etc.; Rrepresents e.g. an optionally substituted alkyl group, alkenyl group, alkynyl group, aryl group, heteroaryl group, pyridinone group, pyrimidinone group or piperadinone group; Ar represents e.g. an optionally substituted aryl or heteroaryl group; and Q and W are the same as or different from each other and each represents N or CH), a pharmacologically acceptable salt or hydrates thereof.

Condensed imidazole compounds and a therapeutic agent for diabetes mellitus

Growing community of inventors

Ibaraki, Japan

Hiroshi Akamatsu